Clinical trial
Phase 1 Study of Lenvatinib in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic RCC
NCT02454478 is registered in ClinicalTrials.gov with Eisai Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase 1 Study of Lenvatinib in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic RCC
- Lead sponsor
- Eisai Co., Ltd.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- July 1, 2015
- Completion date
- May 29, 2017
- Enrollment
- 7 (actual)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.